Lantern Deferred Long Term Liab from 2010 to 2025
| LTRN Stock | USD 3.55 0.17 4.57% |
Deferred Long Term Liabilities | First Reported 2010-12-31 | Previous Quarter 91.1 K | Current Value 116.9 K | Quarterly Volatility 44.7 K |
Check Lantern Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lantern Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 211.1 K, Interest Expense of 246.8 K or Selling General Administrative of 4.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.0017. Lantern financial statements analysis is a perfect complement when working with Lantern Pharma Valuation or Volatility modules.
Lantern | Deferred Long Term Liab |
Latest Lantern Pharma's Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of Lantern Pharma over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Lantern Pharma's Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lantern Pharma's overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
Lantern Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 157,674 | |
| Geometric Mean | 150,885 | |
| Coefficient Of Variation | 28.34 | |
| Mean Deviation | 41,657 | |
| Median | 191,000 | |
| Standard Deviation | 44,691 | |
| Sample Variance | 2B | |
| Range | 99.9K | |
| R-Value | (0.83) | |
| Mean Square Error | 673.5M | |
| R-Squared | 0.69 | |
| Significance | 0.000075 | |
| Slope | (7,771) | |
| Total Sum of Squares | 30B |
Lantern Deferred Long Term Liab History
About Lantern Pharma Financial Statements
Lantern Pharma investors utilize fundamental indicators, such as Deferred Long Term Liab, to predict how Lantern Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 91.1 K | 116.9 K |
Check out the analysis of Lantern Pharma Correlation against competitors. To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.